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Abstract
Background—This current study was undertaken to carefully assess the accuracy of routinely 
used laboratory tests in detecting excessive/recent alcohol use. We also determined the kinetics of 
these markers in subjects who underwent intensive alcohol rehabilitation program.
Methods—The study cohort consisted of 210 non-excessive drinkers, 272 excessive drinkers, 
and 76 with alcoholic cirrhosis. To determine the kinetics of these markers during alcohol 
abstinence, we followed 45 subjects with history of excessive alcohol use for 12-week during the 
intensive alcohol treatment program.
Results—%CDT provided the highest diagnostic performance (AUC 0.77) followed by GGT 
(AUC 0.68) to detect excessive drinkers. The percentage of excessive drinkers with AST:ALT > 2 
was only 2%; whereas, 51% of subjects with alcoholic cirrhosis had AST:ALT > 2. In the 
multivariate analysis, the levels of GGT and %CDT were associated with the level of alcohol 
consumed during the past 30 days. The levels of GGT, MCV, and %CDT were significantly lower 
compared to those at baseline before alcohol rehabilitation whereas the AST, ALT, and AST:ALT 
ratio were unchanged. The percent reduction was ~ 2.7% (for MCV), 19% (for GGT), and 43% 
(for %CDT) at the end of 12-week follow up compared to the baseline.
Conclusions—%CDT, are useful markers to screen for excessive alcohol use and for follow up 
of abstinence. Most subjects with excessive alcohol use do not high AST:ALT ratio. Rather, the 
AST:ALT > 2 is suggestive of alcoholic cirrhosis. The performance of the %CDT to screen for 
heavy alcohol use is still not ideal. Further research to identify the non-invasive marker(s) (i.e. 
using proteomic or metabolomics approach) should be considered.
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INTRODUCTION
Screening for ongoing and excessive alcohol use is of importance especially in patients with 
underlying chronic liver diseases. Ongoing alcohol drinking can exacerbate hepatitis C 
infection and the underlying liver injury, thereby accelerating disease progression 
(Hajarizadeh, Grebely, and Dore 2013). It also has the adverse effect on the response rates to 
anti-viral treatment (Younossi et al. 2013). Assessment of ongoing alcohol use is essential in 
patients with alcoholic liver disease, in which no specific treatment exists and abstinence is 
the mainstay of therapy (Chayanupatkul and Liangpunsakul 2014). Excessive alcohol use 
may impose the detrimental effect in those with underlying non-alcoholic fatty liver disease 
(NAFLD); as it might increase levels of pro-inflammatory cytokines, such as tumor necrotic 
factor-alpha and monocyte chemotactic protein-1, which can worsen liver injury by causing 
inflammatory responses in the hepatocytes (Liangpunsakul and Chalasani 2012).
In general clinical practice, identification of patients with excessive alcohol use can lead to 
early behavioral interventions which will reduce the risk for medical, social, and 
psychological problems (Lee and Pham 2014). Taken together, the detection of excessive 
drinking and prompt intervention with counseling or referral to addiction specialist is crucial 
and should be part of the comprehensive care for patients in general practice.
Excessive drinking is defined as men who drink more than 4 standard drinks in a day (or 
more than 14 per week) and women who drink more than 3 standard drinks in a day (or 
more than 7 per week). Screening for excessive drinking can be obtained through the 
construct interview formats using questionnaires, such as AUDIT, CAGE, or reports from 
collateral family with direct interaction with patients(Knight et al. 2003). However, 
limitations of this approach are most apparent in patients with underlying liver disease 
where individuals have the tendency to minimize the magnitude of drinking behavior to 
mitigate personal ramifications (such as to prevent the denial for hepatitis C therapy or the 
eligibility for liver transplant evaluation(Freeman and Vrana 2010).
Besides questionnaires, several lab tests such as gamma-glutaryltransferase (GGT), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), mean corpuscular volume 
(MCV), and carbohydrate deficient transferrin (CDT) have been routinely used clinically to 
screen for excessive alcohol use (Allen and Anton 2003; Freeman and Vrana 2010; Bearer, 
Bailey, and Hoek 2010; Liangpunsakul et al. 2010). An elevated serum AST to serum ALT 
has been proposed as an indicator that alcohol has induced organ damage. When AST/ALT 
ratio is > 2, it is highly considered as highly suggestive of alcoholic liver cirrhosis (Nyblom 
et al. 2004). However, the role of AST:ALT > 2 to screen for excessive alcohol use, notably 
in those without advanced alcoholic liver disease is inconclusive. In fact, one study showed 
the poor diagnostic performance of this ratio to detect heavy alcohol use (Nyblom et al. 
2004). Serum liver enzymes, surprisingly, have been used widely despite the fact that they 
can be abnormal secondary to underlying liver diseases such as hepatitis C or NAFLD. In 
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this context, other non-hepatic enzyme markers such as CDT might be more accurate and 
useful (Bearer, Bailey, and Hoek 2010).
Previous studies have determined the sensitivity and specificity of these lab tests to stratify 
those with and without excessive alcohol use (Das, Dhanya, and Vasudevan 2008). 
However, none had reported the correlation of these markers with the amount of alcohol 
consumed. This current study was undertaken to carefully assess the accuracy of routinely 
used laboratory tests in detecting excessive and recent alcohol use in a large cohort of 
subjects with history of alcohol use disorder. Further, we also determined the kinetics of 
these markers once the patient’s alcohol consumption has stopped in the cohort of subjects 
who underwent intensive alcohol rehabilitation program. The results of this study is of 
importance as it will provide us the information on the usefulness of these commonly used 
markers to screen for recent excessive alcohol use and monitor for abstinence.
METHODS
STUDY COHORT
To determine the performance of commonly used lab tests and levels of alcohol 
consumption, we recruited 272 subjects with history of alcohol use disorder (AUD) who 
were admitted for alcohol rehabilitation at Fairbanks Drug and Alcohol Treatment Center 
(Indianapolis, IN). All subjects met the criteria for AUD (defined by the DSM IV criteria) 
and ‘excessive drinking’ as defined by NIH/NIAAA. They reported the last use of alcohol 
within 0–72 hrs before the enrollment. Two hundred and ten non-excessive drinkers were 
recruited from Richard L. Roudebush Veterans Administration Medical Center (RLR 
VAMC, Indianapolis, IN). These were the healthy subjects who attended the outpatient visit 
for routine health examination. We used multiple avenues to ensure that each subject did not 
have excessive alcohol consumption including medical record review, intensive face to face 
interview with research coordinator, screening using AUDIT-C and time line follow-back 
questionnaires. All were at least 21 years of age or older and be able to provide informed 
consent. Subjects were excluded if they had active and serious medical diseases (such as 
congestive heart failure, chronic obstructive pulmonary disease, cancer, uncontrolled 
diabetes, and chronic renal failure); past history of jaundice or signs of end stage liver 
disease (such as ascites, hepatic encephalopathy, or variceal bleeding) had history of chronic 
hepatitis B/C infection, had history of any systemic infection within 4 weeks prior to the 
study; or had history of recent major surgeries within the past 3 months. To further explore 
whether AST:ALT ratio is an indicative of excessive alcohol use or advanced alcoholic liver 
disease, we also included another cohort of subjects with known diagnosis of alcoholic liver 
disease (ALD, n=76) who attended the liver clinic or pre liver transplantation clinic at the 
Indiana University (Whitfield et al. 2015). All subjects with ALD had alcohol consumption 
averaging at least 80 g per day (for men) or 50 g per day (for women), for at least 10 years. 
These cases had evidence of cirrhosis as per clinical signs, radiographic imaging results 
(sonography, computed tomography, magnetic resonance imaging) compatible with 
cirrhosis and/or history of ascites, grade 2 or higher spontaneous hepatic encephalopathy 
and/or the presence of esophageal varices on upper gastrointestinal endoscopy, or biopsy-
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proven cirrhosis, with exclusion of hepatitis B or C, autoimmune liver disease, 
hemochromatosis, and Wilson’s disease (Whitfield et al. 2015).
To determine the kinetics of the routinely used markers after alcohol abstinence, we 
prospectively recruited another 45 subjects with history of excessive alcohol use who 
enrolled in a 12-week intensive alcohol treatment program at Fairbanks. All subjects were 
closely followed by the psychiatrist/addiction specialist to confirm the abstinence while 
enrolling in the program. Blood tests were drawn at baseline (before starting the program) 
and at week 1, 2, 3, 4, 6, 8, 10 and 12 (the end of treatment). All subjects reported the last 
use of alcohol within 0–72 hrs before the initiation of the program. All complied with the 
treatment and none relapsed to excessive alcohol use. The study design and protocol were 
approved by the Institutional Review Board at the Indiana University Purdue University 
Indianapolis (IUPUI), RLR VAMC Research and Development Program, and at Fairbanks 
Alcohol Rehabilitation Center. Written informed consent was obtained from each participant 
at the screening interview.
Data Collection and clinical evaluation
Control subjects and those with excessive alcohol use completed a self-administered 
questionnaire. Demographic data, smoking history, past medical history, and the Alcohol 
Use Disorders Identification Test (AUDIT-C) were collected. In this study, the Time Line 
Follow-Back (TLFB) questionnaire was used to determine the amount of alcohol 
consumption over the 30-day period before the study date. It was administered in person by 
trained study coordinators who reviewed the instructions with the subjects prior to 
administering the questionnaire. The TLFB offers a retrospective report of daily alcohol 
consumption over the past 30 days; drinks per drinking occasion, and pattern of drinking can 
be computed (Sobell et al. 1988; Sobell et al. 2003; Vakili et al. 2008). The levels of serum 
AST, ALT, GGT and MCV were analyzed at our Clinical Pathology laboratory. %CDT 
(with the reference normal range <2.5%) was performed at Quest Diagnostics.
Statistical analysis
Basic descriptive statistics, including mean, standard deviations (S.D), and frequencies 
(percentages) were used to characterize the study subjects for each of the cross-sectional 
study and the follow up cohort. Appropriate comparison tests including chi-square test, 
student t-test, and ANOVA were used for comparison between/among groups for categorical 
and continuous variables For the cross-sectional data set (n=210 for non-excessive drinkers 
and n=272 for excessive drinkers), the receiver operating characteristic (ROC) analysis was 
utilized to estimate the utility of commonly used serum markers in detecting excessive 
alcohol use. The area under the curve (AUC) derived from the ROC analysis for each 
marker was compared. The ROC-based optimized threshold was computed by finding the 
cutoff that maximized the sum of specificity and sensitivity. Sensitivity, specificity, positive 
predictive values (PPVs), and negative predictive values (NPVs) for the individual markers 
were calculated for marker-specific cutoff values. In addition, multivariate linear regression 
with each marker as the dependent variable and alcohol consumption as the predictor was 
used to determine the relationship between the concentrations of each marker and the 
amount of alcohol consumption in the past 30 days before the enrollment. The regression 
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models were assessed for linearity and normality using the residual plots and no violation of 
model assumption was detected. For the analyses of AST:ALT, we divided the AST:ALT 
into 3 groups; AST:ALT >2, 1≤AST:ALT≤2, and AST:ALT<1. The percentages of subjects 
in controls, excessive drinkers, and those with ALD for each AST:ALT group were 
calculated and compared for the differences using chi-square test.
For the follow up cohort (n=45), the linear mixed-effect models with time as the main 
predictor, a random intercept for subject effect, were used to determine whether there were 
significant time trend in the serum concentration of the markers of interest during the 12-
week follow up period and to determine the rate of changes for each marker, if any, over 
time. All analyses were conducted with SAS software version 9.3 (Cary, NC).
Results
Clinical characteristics of the study cohort
During the study period, 482 subjects were recruited (210 non-excessive drinkers and 272 
excessive drinkers). Subject characteristics are summarized in Table 1. Excessive drinkers 
were older, had higher percentage of divorce/separation, and had lower BMI, when 
compared to those of non-excessive drinkers. Excessive drinkers had higher AUDIT scores 
(26.9 vs. 4.7, p<0.001), greater total standard drinks in the past 30 days (257 vs. 13 drinks, 
p<0.001), higher average drinks per drinking day (12.9 vs 2.5 drinks, p<0.001), and a higher 
number of drinking days in the past month (20 vs. 4.5 days, p<0.001), when compared to 
controls. They had significantly higher levels of serum AST, GGT, MCV and %CDT. We 
observed the higher concentrations of ALT in non-excessive drinkers, likely due to the 
higher BMI of subjects in this group, compared to excessive drinkers (50.7 vs. 36.5, p < 
0.001). When we used the cut off reference for %CDT provided by the laboratory (>2.5% 
considered being abnormal), we found that 5.2% of controls and 44.2% of excessive 
drinkers had abnormal %CDT.
The utility of the routinely used serum markers to detect excessive alcohol use
The ROC curves and AUC values for all measured biomarkers in stratifying the excessive 
drinking status are shown in Figure 1. %CDT provided the highest diagnostic performance 
to detect excessive alcohol use with an AUC 0.77, followed by GGT with an AUC of 0.68, 
MCV with an AUC of 0.66, AST with the AUC of 0.61, and ALT with the AUC of 0.29. 
The AUC for %CDT was significantly higher than that of GGT (p=0.001), MCV (p = 
0.002), AST (p=0.0015), and ALT (p=0.0001). The results of application of these markers 
using the optimal cutoff in detection of excessive alcohol use are shown in Table 2.
Association between the levels of serum markers and the amount of alcohol consumption 
in the last 30 days
We next determined the relationship between the levels of serum markers and the amount of 
alcohol consumption in the past 30 days (Figure 2). The results of the multivariate 
regression models and Person’s correlation are shown in Table 3. In the multivariate 
analysis, we found that GGT (r = 0.31, p <0.001) and %CDT (r = 0.15, = 0.04) were 
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associated with the level of alcohol consumed during the past 30 days prior to the 
enrollment.
AST:ALT ratio in controls, excessive drinkers and subjects with alcoholic cirrhosis
The baseline characteristics of 76 subjects with alcoholic cirrhosis were shown in Table 4. 
These subjects had significant higher levels of AST and GGT, but lower levels of ALT, 
when compared to controls and excessive drinkers without liver diseases (p<0.001). The 
percentages of subjects in controls, excessive drinkers, and those with alcoholic cirrhosis 
stratified by the AST:ALT ratio were shown in Figure 3. Among those with excessive 
alcohol use, 46.3% had AST:ALT < 1 and 51.5% had the ratio between 1 and 2. 
Interestingly, the percentage of subjects with AST:ALT > 2 was only 2%. Most controls had 
the AST:ALT ratio < 1 (95%). However, 51% of subjects with alcoholic cirrhosis had 
AST:ALT > 2; which was statistically higher than that in controls and excessive drinkers 
(P<0.0001).
Trends/kinetics of the routinely used serum markers after alcohol abstinence
To study the utility of these markers as for follow up of abstinence in clinical practice, we 
prospectively followed 45 subjects with history of excessive alcohol use who enrolled in a 
12-week intensive alcohol treatment program at Fairbanks. The demographic and clinical 
characteristics of these subjects are shown in Table 5. These subjects had the mean AUDIT 
scores of 28.7, an average of 234 drinks in the past month, and had ~ 12 drinks per drinking 
day. The mean serum concentrations for AST, ALT, AST:ALT ratio, and GGT were 26, 
24.8, 1.13, and 74.3 U/L, respectively (these levels were not statistically different compared 
to those of 272 subjects shown in Table 1). In this prospective cohort, we again found that 
none of the 45 subjects had the AST:ALT ratio > 2, indicating the poor diagnostic 
performance of using the ratio to screen for excessive alcohol use without advanced liver 
disease. During the follow up period, only the levels of GGT, MCV, and %CDT were 
significantly lower compared to those at baseline before alcohol rehabilitation. The rate of 
decline was 1.2 unit/week for GGT, 0.21 unit/week for MCV, and 0.09 unit/week for %CDT 
(Figure 4, Table 6). During the course of the follow up, the average levels of AST, ALT, and 
AST:ALT ratio were unchanged.
DISCUSSION
Excessive alcohol use is not uncommon among patients with underlying liver disease and 
those who are seen in general medicine clinics (Lee and Pham 2014; Jackson et al. 2010). 
Numerous studies have shown the adverse effects of ongoing excessive alcohol use (Taylor 
et al. 2007; Mathurin 2005). Therefore, screening for alcohol use, appropriate counselling, 
and ensuring abstinence are necessary when providing medical cares to these patients.
The under detection of excessive alcohol use in the routine care of patients has been found 
when using the self-report or questionnaire administration to estimate alcohol 
consumption(Bearer, Bailey, and Hoek 2010). In contrast to self-report questionnaires, 
serum markers can objectively and reliably detect the problem drinking or track the 
abstinence. Several routinely used markers for excessive alcohol use have been studied such 
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as serum AST, ALT, and GGT(Bearer, Bailey, and Hoek 2010; Liangpunsakul et al. 2010). 
Unfortunately, the baseline levels of these markers, a panel of liver enzymes, may be 
perturbed from underlying liver disease such as hepatitis C or NAFLD, but not from 
excessive alcohol use per se. Other non-hepatic enzyme markers have been used, e.g. MCV 
and %CDT (Das, Dhanya, and Vasudevan 2008). Heavy alcohol use causes the alteration in 
the lipid structure of red cell membrane, leading to the increase in the MCV values 
(Liangpunsakul et al. 2010). Transferrin molecules in the blood usually contain several 
carbohydrate components. In chronic heavy drinkers, however, the number of carbohydrate 
components in each transferrin molecule is reduced, resulting in the increase in 
%CDT(Golka et al. 2004).
We found that the commonly used markers have fairly low sensitivities to detect excessive 
alcohol use. %CDT had the highest sensitivity, followed by GGT. However, few conditions 
other than heavy drinking will elevate CDT levels, thus decreasing the probability of false 
positive results by using CDT as the marker. %CDT might also be a better marker than GGT 
as other chronic liver diseases also can increase GGT levels, increasing the likelihood of 
false-positive results. The sensitivity of AST and ALT was ~43% and 4%, respectively, and 
thus they should not be used as the surrogates to screen for excessive alcohol use.
Traditionally, AST:ALT ratio > 2 is considered as highly suggestive of alcohol-induced liver 
injury, notably alcoholic cirrhosis (Nyblom et al. 2004). However, the diagnostic 
performance of using the cut-off ratio to detect excessive drinking without significant liver 
disease is still debatable. Our study provided the important insight into the use of AST:ALT 
ratio in the context of excessive alcohol use, and in advanced alcoholic liver disease/
cirrhosis. We found that most patients with excessive alcohol consumption but without 
clinical evidence of advanced liver disease did not have AST:ALT ratio > 2. In fact, our 
results are in accordance with previous report showed that many patients who consume high 
amounts of alcohol and in deed are alcohol dependent with elevated serum aminotransferase 
levels do not show the high AST:ALT ratio (Nyblom et al. 2004). High AST:ALT ratio (>2) 
suggests the presence of advanced alcoholic liver disease/cirrhosis. The explanation for 
AST:ALT>2 in alcoholic liver cirrhosis is the decreasing in ALT activity or pyridoxal 5′-
phosphate depletion (Diehl et al. 1984; Matloff, Selinger, and Kaplan 1980). However, the 
reason on why in excessive drinkers without alcoholic liver disease did not have high 
AST:ALT ratio is not clear, though it is possible that ongoing and excessive alcohol 
drinking might have direct toxic effect on both AST and ALT (Nyblom et al. 2004).
We found the statistical significance between the serum GGT and %CDT and the alcohol 
consumed in the past 30 days before testing. However, the results may not be clinically 
meaningful. We found that the regression coefficient, representing the mean change in the 
response variable (the serum levels of each marker) for one unit of change in the predictor 
variable (the level of alcohol consumption), was low. This indicated that for every additional 
drink, we can expect the changes in the markers of interest by an average of 0.003 (for CDT) 
to 0.15 (for GGT). So while both might be useful in detection of excessive alcohol use, it 
might not be helpful for its use to correlate to the amount of alcohol being consumed by 
patient in the past month.
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The rate of decline of the marker of interest after abstinence is a crucial information in 
clinical practice. In patients in whom the regression in the level of these markers is not what 
we expected, it might be an indicative of concealed, ongoing alcohol drinking. Among these 
markers, we found that only MCV, GGT, and %CDT had the significant decline over time, 
at the rate of 0.21, 1.20, and 0.10 unit/week, respectively. At the end of 12 weeks follow up, 
the total decline for MCV, GGT, and %CDT was ~2.52 fL, 14.4 U/L, and 1.2%, 
respectively. When compared the decrease in these values to the average levels of these 
markers at baseline (MCV 93 fL, GGT 74 U/L, and % CDT 2.8%), the reduction was ~ 
2.7% (for MCV), 19% (for GGT), and 43% (for %CDT) as shown in Table 6. There were no 
changes in the AST, ALT and AST:ALT ratio during the follow up period. Our data 
indicated that, among these markers, %CDT is the best marker to track the abstinence with 
the significant reduction ~43% (compared to baseline when patient stopped drinking) at 12 
weeks follow up.
Several limitations deserve discussion. It is difficult to determine the ‘true’ cases for specific 
diseases; in which no ‘objective’ tests exist – in our scenario – subjects with excessive 
alcohol drinking. To minimize this drawback, we thus recruited the subjects from an alcohol 
rehabilitation hospital, in whom they have been screened and diagnosed by the addiction 
specialist with alcohol use disorder. On the average, these subjects have history of excessive 
alcohol consumption for at least 5 years, consumed alcohol almost daily, and the last alcohol 
consumption was within 72 hours prior to enrollment. For the recent alcohol consumption 
history (during the past 30 days), we relied on self-report questionnaire, TLFB, as our 
reference. This instrument rates high in validity and reliability for determining daily alcohol 
intake, and is the standard instrument used by alcohol researchers for quantifying daily 
drinking(Carey et al. 2001).
In summary, our data showed that %CDT, are useful markers to screen for excessive alcohol 
use and for follow up of abstinence. Most subjects with excessive alcohol use do not high 
AST:ALT ratio. Rather, the AST:ALT > 2 is suggestive of alcoholic cirrhosis. The 
performance of the %CDT to screen for heavy alcohol use is still not ideal. Further research 
to identify the non-invasive marker(s) (i.e. using proteomic or metabolomics approach) 
should be considered.
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LIST OF ABBREVIATIONS
AST Aspatate alanine transferase
ALT alanine aminotransferase
%CDT Percentage of carbohydrate deficient transferin
GGT Gamma-glutaryltransferase
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MCV Mean Corpuscular volume
MELD Model for end stage liver disease
TLFB Timeline follow back
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FIGURE 1. 
The ROC and Area under the curve with 95% confidence interval for all measured 
biomarkers in stratifying the excessive drinking status
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FIGURE 2. 
The linear regression analyses between the levels of serum markers and the amount of 
alcohol consumption in the past 30 days. The dark linear line representing the best-fit line 
from the linear regression analysis with its 95% confidence interval (dotted line)
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FIGURE 3. 
Percentage of subjects in controls, excessive drinkers, and alcoholic cirrhosis with the 
AST:ALT ratio > 2, 1≤AST:ALT≤2, and AST:ALT < 1
Gough et al. Page 13
Alcohol Clin Exp Res. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
FIGURE 4. 
Levels of biomarkers of interest during the 12-week alcohol rehabilitation
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Table 1
Baseline demographic and alcohol drinking characteristics of the study cohort
Demographic and clinical characterstics Non excessive drinkers/Controls 
(n = 210)
Excessive drinkers (n =272) p-value
Age (years) 32.5±8.6 39.7±11.8 <.0001
Male sex, n (%) 180 (85.7%) 182 (66.9%) <.0001
Race, White, n (%) 168 (80%) 220 (81%) 0.22
Marital status (%) 0.001
: Married 54.3 35.3
: Divorced/separated 18.1 28.3
: Never married 19.1 27.9
: Others 8.5 8.5
BMI (kg/m2) 29.9±14.31 27.9±5.51 0.05
AUDIT-C 4.7±5.67 26.9±7.75 <.0001
Alcohol drinking patterns during the last 30 days from TLFB
: Total drinks 13.3±15.3 257.7±176.5 <.0001
: Number of days drinking last 30 days 4.5±5.3 20.1±6.2 <.0001
: Average drinks per drinking day 2.5±2.9 12.9±7.5 <.0001
: Average drinks per day 0.5±0.5 8.6±5.8 <.0001
: Greatest number of drinks in one day 3.9±3.2 18.6±8.92 <.0001
Laboratory measures
: Serum AST (U/L) 26.0±22.0 38.9±75.5 0.008
: Serum ALT (U/L) 50.7±1.8 36.5±1.9 <.0001
: Serum GGT (U/L) 35.6±31.1 85.5±126.10 <.0001
: %Carbohydrate deficient transferrin (%CDT) 1.9±3.7 2.6±1.2 0.023
: Mean Corpusular volume (fL) 89.5±4.3 93.4±20.1 0.002
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Table 3
Multivariate regression models and Pearson’s correlation coefficient of the association between the levels of 
serum markers and the amount of alcohol consumed in the past 30 days
Biomarkers Regression coefficient (95% CI) Pearson’s correlation coefficient P-value*
AST 0.02 (−0.02−0.06) 0.12 0.06
ALT −0.01 (−0.03−0.003) −0.08 0.11
GGT 0.15 (0.10–0.21) 0.31 <.0001
MCV 0.008 (0.00007–0.02) 0.10 0.05
CDT 0.003 (0.003–0.005) 0.15 0.04
*p-value for coefficients in the regression models. The model was adjusted for age, gender, race, and BMI
Alcohol Clin Exp Res. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Gough et al. Page 18
Table 4
Baseline demographics and clinical characteristics of subjects with alcoholic cirrhosis (N=76)*
Demographic and clinical characterstics N=76
Age (yrs) 49.4±9.2
Male sex, n (%) 75
Race, White, n (%) 91
MELD scores 13.1±7.6
Child-Pugh Classification (%)
A 63
B 30
C 7
Laboratory measures
: platelet counts (cells/mm3) 140.2±72
: albumin (g/dl) 3.0±0.6
: AST (U/L) 48.9±33
: ALT (U/L) 27±17
: GGT (U/L) 156±84
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Table 5
Baseline demographic and alcohol drinking characteristics of 45 subjects who underwent intensive alcohol 
rehabilitation program
Demographic and clinical characterstics N=45
Age (yrs) 37.9±11.73
Male sex, n (%) 25 (55.6%)
Race, White, n (%) 37 (83%)
Marital status
: Married 17 (37.8%)
: Divorced/separated 8 (17.8%)
: Never married 17 (37.8%)
: Others 3 (6.6%)
BMI (kg/m2) 26.9±4.40
AUDIT-C 28.7±6.55
Alcohol drinking patterns during the last 30 days from TLFB
: Total drinks 234.0±150.40
: Number of days drinking last 30 days 18.7±6.89
: Average drinks per drinking day 12.3±5.51
: Average drinks per day 7.8±5.01
: Number of heavy drinking days 15.9±7.78
: Greatest number of drinks in one day 18.7±8.71
Laboratory measures
: Serum AST (U/L) 26.0±13.87
: Serum ALT (U/L) 24.8±11.52
: Serum GGT (U/L) 74.3±111.80
: Mean Corpusular volume (fL) 92.9±5.32
: Serum %Carbohydrate deficient transferrin (%CDT, %) 2.83±1.2
: AST:ALT ratio 1.13±0.4
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Table 6
Adjusted associations between average weekly decline, and percent of reduction compared to baseline in the 
serum markers of interest and time of follow up in 45 subjects who underwent 12-week intensive alcohol 
rehabilitation program$
Biomarker Coefficient of the time effect Reduction (%)* P-value**
MCV −0.21 2.7 <.0001
AST −0.09 N/A 0.5893
ALT 0.33 N/A 0.2868
GGT −1.20 19 0.0040
CDTA −0.10 43 <.0001
AST:ALT 0.21 N/A 0.47
*percent reduction was based off decrease in these values to the average levels of these markers at baseline before the alcohol rehabilitation 
program
**p-value is reflective of the coefficient of the time effect. The model was adjusted for age, gender, race, and BMI
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